Catapres Shortage: What Providers and Prescribers Need to Know in 2026

Catapres Shortage: A Provider Briefing for 2026

The discontinuation of brand-name Catapres (Clonidine Hydrochloride) by Boehringer Ingelheim in 2022 continues to create confusion and access challenges for patients in 2026. While the active pharmaceutical ingredient remains widely available in generic form, prescribers should understand the current landscape to manage patient expectations and ensure continuity of care.

This briefing covers the timeline, current availability, prescribing considerations, cost and access issues, and tools to help your patients stay on therapy.

Timeline: What Happened to Catapres

Understanding the history is important for addressing patient concerns:

• October 2021: Boehringer Ingelheim issued a voluntary recall of certain lots of Catapres tablets due to failed dissolution testing (tablets not dissolving within specifications)
• Early 2022: Boehringer Ingelheim permanently discontinued manufacturing of both Catapres tablets (0.1 mg, 0.2 mg, 0.3 mg) and Catapres-TTS transdermal patches (0.1, 0.2, 0.3 mg/day)
• May 2023: The FDA published a formal determination that Catapres was not withdrawn for reasons of safety or effectiveness, allowing continued ANDA approvals for generic Clonidine
• 2023-2025: Periodic spot shortages of generic Clonidine transdermal patches as manufacturers adjusted to increased demand
• 2026: Generic Clonidine tablets are widely available; patch availability is improved but may still be intermittent at some pharmacies

Prescribing Implications

Update Prescriptions Written for Brand-Name Catapres

The most common access issue reported by patients is having an active prescription for "Catapres" with a DAW (Dispense as Written) code. Pharmacists cannot substitute generic Clonidine if DAW is specified. Review active prescriptions for patients on Clonidine and update to generic Clonidine HCl if brand-specific designation remains.

Formulation Considerations

Clonidine is currently available in several formulations, each with clinical implications:

• Immediate-release tablets (0.1 mg, 0.2 mg, 0.3 mg): Most widely available and affordable. Require twice-daily dosing (BID), with the larger dose typically at bedtime to mitigate daytime sedation. Available from multiple generic manufacturers
• Extended-release tablets (Kapvay, Onyda XR, generics): FDA-approved for ADHD in pediatric patients aged 6-17. Generally available, though some strengths may have limited supply. Once- or twice-daily dosing depending on the product
• Transdermal patches (generic Catapres-TTS): Applied weekly. May still experience intermittent supply constraints. Useful for patients with adherence challenges or those who cannot take oral medications. Note: skin irritation is more common with patches, and therapeutic onset is slower (2-3 days to steady state)
• Epidural injection (Duraclon): Reserved for severe cancer pain management in appropriate settings

Rebound Hypertension Risk

The most critical clinical consideration when Clonidine is unavailable is rebound hypertension. Abrupt discontinuation can cause sympathetic overdrive within 18-72 hours, manifesting as:

• Severe hypertension (potentially exceeding pre-treatment levels)
• Tachycardia, agitation, tremor
• Headache, nausea, diaphoresis
• Rarely: hypertensive encephalopathy or stroke

Mitigation: When transitioning patients off Clonidine (whether due to supply issues or clinical decision), taper by 0.1 mg every 3-7 days. If concurrent beta-blocker therapy exists, discontinue the beta-blocker first, then taper Clonidine to avoid unopposed alpha stimulation.

For a patient-facing overview of side effects, see Catapres Side Effects: What to Expect.

Current Availability Picture

As of early 2026, the availability landscape for Clonidine products is:

• Tablets (IR): ✅ Widely available — no active shortage
• Tablets (ER): ✅ Generally available — occasional limited supply on specific strengths
• Transdermal patches: ⚠️ Intermittently available — check stock before prescribing
• Brand Catapres: ❌ Permanently discontinued
• Brand Catapres-TTS: ❌ Permanently discontinued

Providers can use Medfinder for Providers to check real-time pharmacy stock before writing or adjusting prescriptions.

Cost and Access Considerations

Cost is generally not a barrier for generic Clonidine IR tablets, but may impact access for other formulations:

• Generic Clonidine IR tablets: Cash price $15-$30 for 30-day supply; as low as $4-$10 with discount cards. Tier 1 on most formularies
• Generic Clonidine ER tablets: Cash price $170-$240; about $18-$25 with coupons. May require prior authorization for ADHD indication on some plans
• Generic transdermal patches: Cash price $100-$175 for 4 patches; coupon prices vary. Often Tier 2 or 3 on formularies

For patients experiencing cost barriers, discount cards (GoodRx, SingleCare), the Walmart $4 list (which includes Clonidine tablets), and patient assistance programs through NeedyMeds or RxAssist may help. See the patient guide: How to Save Money on Catapres.

For provider-specific cost guidance, see How to Help Patients Save Money on Catapres: A Provider's Guide.

Tools and Resources for Providers

Medfinder for Providers

Medfinder for Providers allows you to check which pharmacies in your patient's area have Clonidine in stock. This can be done during the clinical encounter to ensure the patient can actually fill the prescription being written.

Formulary and Prior Authorization Resources

When switching between Clonidine formulations or to alternatives like Guanfacine, check the patient's formulary to avoid prior authorization delays. Common considerations:

• IR Clonidine for hypertension: rarely requires PA
• ER Clonidine (Kapvay generic) for ADHD: may require step therapy (trial of IR first) or PA
• Guanfacine ER (Intuniv generic) for ADHD: may require PA on some plans

Alternative Medications

If Clonidine is unavailable or clinically inappropriate, consider:

• Guanfacine (Tenex/Intuniv): Same class (alpha-2 agonist). Longer half-life, once-daily dosing, possibly less sedating. FDA-approved for both hypertension and pediatric ADHD
• Methyldopa: Centrally-acting antihypertensive with established pregnancy safety profile
• Amlodipine, Hydrochlorothiazide, or ARBs: For hypertension-only indications, first-line agents per ACC/AHA guidelines may be clinically preferable

For a detailed comparison, see Alternatives to Catapres.

Looking Ahead

The generic Clonidine market appears stable heading into late 2026. Multiple manufacturers produce immediate-release tablets, and the extended-release market has additional options with Onyda XR generics. The main area of concern remains transdermal patch availability, which may continue to experience periodic supply disruptions.

Providers should proactively review their patient panels for any prescriptions still written for brand-name Catapres and update them to generic Clonidine. For patients on the patch formulation, consider discussing tablet alternatives as a backup plan.

Final Thoughts

The Catapres discontinuation was a manageable disruption, but it continues to cause patient confusion and access issues four years later. By keeping prescriptions current, monitoring formulary requirements, and using tools like Medfinder for Providers to verify stock, prescribers can minimize gaps in therapy and ensure patients maintain continuity of care.

For a practical step-by-step guide, see How to Help Your Patients Find Catapres in Stock.